Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	SEK 7.750	-2.52%	53,137
03/26/03	SEK 7.950	-11.67%	11,960
02/26/02	SEK 9.000	+2.86%	555
01/26/01	SEK 8.750	-3.85%	8,082
31/26/31	SEK 9.100	-0.55%	308

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 09:30:00 04/09/2026 pm IST			5-day change	1st Jan Change
7.750 ^SEK	-2.52%		-15.30%	-54.28%

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE

Market Cap	15Cr 1.53Cr 1.32Cr 1.24Cr 1.13Cr 2.12Cr 144.5Cr 2.12Cr 5.68Cr 74Cr 5.75Cr 5.62Cr 238.83Cr	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	13Cr 1.31Cr 1.13Cr 1.06Cr 97.24L 1.82Cr 124.14Cr 1.82Cr 4.88Cr 64Cr 4.94Cr 4.83Cr 205.18Cr	EV / Sales 2024	7.85x	EV / Sales 2025	5.87x
Free-Float	23.31%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	PRO	Delayed
Deutsche Boerse AG	B0T	Delayed
Börse Stuttgart	B0T	Delayed
Boerse Muenchen	B0T	Real-time

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
19/05	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Promimic nomination committee proposes new chairman	RE
24/02	Promimic Q4 net sales SEK 11.5 mln	RE
24/02	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
19/11	Promimic Q3 sales of SEK 12.9 mln	RE
19/11	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/25/22	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/25/11	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/25/15	Promimic reports slightly lower operating loss	FW
15/25/15	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/25/15	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Promimic AB Share Price

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation : Promimic AB

Chart: Promimic AB

Latest news : Promimic AB

Analysts' recommendations : Promimic AB

Press Releases : Promimic AB

Quotes and Performance

Price Extremes

Managers and Directors : Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-2.52%
1 week	-15.30%
Current month	-14.84%
1 month	-23.27%
3 months	-34.32%
6 months	-40.84%
Current year	-54.28%

1 week	7.7	9.35
1 month	7.7	11.4
Current year	7.7	16.55
1 year	7.7	19.5
3 years	7.7	45
5 years	7.7	45
10 years	7.7	45

Manager	Title	Age	Since
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	01/01/2004
Magnus Larsson CEO	Chief Executive Officer	63	18/01/2017
Heidi Bader DFI	Director of Finance/CFO	45	01/01/2023

Director	Title	Age	Since
Helena Maria Brisby BRD	Director/Board Member	61	01/01/2021
Johan Dighed BRD	Director/Board Member	53	01/01/2021
Pehr Abrahamsson CHM	Chairman	59	21/05/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	1,60,000	0.8685%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	1,25,000	0.6785%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	-2.52%	-15.30%	-48.16%	-72.81%	1.57Cr
LONZA GROUP AG	-2.54%	-2.84%	-1.90%	+14.52%	5.03TCr
REVOLUTION MEDICINES, INC.	-1.12%	+0.41%	+435.92%	+519.59%	4.52TCr
IQVIA HOLDINGS INC.	-1.65%	+2.31%	+45.48%	+21.24%	4.47TCr
BEONE MEDICINES AG	-1.28%	-2.42%	+12.28%	+74.70%	4.12TCr
CELLTRION, INC.	+0.53%	-1.67%	+15.16%	+49.88%	3.31TCr
ASCENDIS PHARMA A/S	-0.55%	+8.66%	-	-	1.78TCr
MEDPACE HOLDINGS, INC.	-0.13%	-1.30%	+22.91%	+123.63%	1.66TCr
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+15.83%	+27.98%	1.48TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.47%	-0.75%	+78.25%	+41.62%	1.4TCr
Average	-1.17%	-0.64%	+63.97%	+88.93%	2.78TCr
Weighted average by Cap.	-1.22%	-0.46%	+93.69%	+126.70%

	2024	2025
Net sales	4.89Cr 51.12L 43.99L 41.39L 37.81L 70.73L 48Cr 70.92L 1.9Cr 25Cr 1.92Cr 1.88Cr 80Cr	5.11Cr 53.37L 45.92L 43.21L 39.47L 73.84L 50Cr 74.04L 1.98Cr 26Cr 2Cr 1.96Cr 83Cr
Net income	-1.26Cr -13.12L -11.29L -10.62L -10L -18.15L -12Cr -18.2L -48.7L -6.35Cr -49.26L -48.19L -20Cr	-87.54L -9L -8L -7L -7L -12.66L -8.64Cr -12.69L -33.97L -4.43Cr -34.36L -33.61L -14Cr
Net Debt	-3.58Cr -37.38L -32.17L -30.27L -27.65L -51.72L -35Cr -51.86L -1.39Cr -18Cr -1.4Cr -1.37Cr -58Cr	-2.06Cr -21.56L -18.56L -17.46L -15.95L -29.83L -20Cr -29.92L -80.05L -10Cr -80.97L -79.21L -34Cr